DVAX News and Press, Dynavax Technologies Corporation From 05/08/24

2024-05-08 19:51:09 ET Dynavax Technologies Corporation (DVAX) Q1 2024 Earnings Conference Call May 08, 2024, 16:30 ET Company Participants Paul Cox - VP, Investor Relations & Corporate Communications Ryan Spencer - CEO Donn Casale - Chief Commercial Officer ...

2024-05-08 17:45:39 ET More on Dynavax Dynavax Technologies: Still A Believer Dynavax: Holding Firm Despite Its Missing Cash Cow Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript Dynavax GAAP EPS of -$0.07 misses by $0.04, revenue of $5...

Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates PR Newswire HEPLISAV-B ® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024 Reaffirming full year 2024&...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

2024-05-07 17:20:42 ET More on Dynavax Dynavax Technologies: Still A Believer Dynavax: Holding Firm Despite Its Missing Cash Cow Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript Dynavax GAAP EPS of $0.00 beats by $0.01, revenue of $55....

2024-05-05 08:00:00 ET As Wall Street embarks on the first full week of May, a diverse group of companies is set to report financial results. Notable names include The Walt Disney Company ( NYSE: DIS ), Palantir Technologies ( NYSE: PLTR ), Realty Income ( NYSE: ...

Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 PR Newswire EMERYVILLE, Calif. , April 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company develo...

2024-03-24 07:39:48 ET Summary Dynavax's core asset, HEPISLAV-B, saw a 69% increase in sales in FY23, making the company cash flow positive. The company's CpG 1018 vaccine candidates are advancing in mid-stage trials, with Heplisav potential sales reaching $400 million by FY27. ...

2024-03-23 08:20:06 ET Summary Pandemic era CpG 1018 revenues are gone and unlikely to rekindle. HEPLISAV-B revenues create a reliable growing stream of income. Dynavax is fairly valued. I have followed the changing fortunes of Dynavax ( DVAX) since 01/2017...

2024-03-22 01:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...